Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Kennedy SP, O'Neill M, Cunningham D, Morris PG, et al. Oncogene 2020 Feb 10. pii: 10.1038/s41388-020-1202.

Read + Share

Amedeo Smart

Independent Medical Education

Kennedy SP, O'Neill M, Cunningham D, Morris PG, et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene 2020 Feb 10. pii: 10.1038/s41388-020-1202.
PMID: 32042115